c-FLIP inhibits chemotherapy-induced colorectal cancer cell death
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 2×
“These assays indicated that cotreatment with FT siRNA and 5-FU resulted in synergistic decreases in cell viability according to the definitions of Chou and Talalay (1984), with combination index (CI) values of o1 for 8/9 concentrations (Figure 2c).”
Method5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“The fluoropyrimidine 5-fluorouracil (5-FU) has been the mainstay of colorectal cancer (CRC) therapy for over 40 years (Longley et al., 2003).”
BackgroundSelf-citationDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“(Douillard et al., 2000; Giacchetti et al., 2000).”
Chinnaiyan, A. M., O'Rourke, K., Tewari, M., & Dixit, V. M. (1995) · Cell · doi:10.1016/0092-8674(95)90071-3 · Cited by 2,431
A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling
Chan, F. K.-M., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2351 · Cited by 856
Yeh, W.-C., Itie, A., Elia, A. J., Ng, M., Shu, H.-B., Wakeham, A., Mirtsos, C., Suzuki, N., Bonnard, M., Goeddel, D. V., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80214-9 · Cited by 515 · cited 1×
“Initially, both proapoptotic and antiapoptotic effects were proposed for c-FLIP; however, data from cell lines stably overexpressing c-FLIP and from mice deficient in c-FLIP support an antiapoptotic function for c-FLIP (Irmler et al., 1997; Yeh et al., 2000).”
BackgroundThe Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex
Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D. W., Briand, C., & Grütter, M. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206882200 · Cited by 482
Aragane, Y., Kulms, D., Metze, D., Wilkes, G., Pöppelmann, B., Luger, T. A., & Schwarz, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.1.171 · Cited by 463
Cited by
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
“High FLIP expression has been found in many tumor cells and has been correlated with resistance to CD95- or TRAIL- and also to chemotherapy-induced apoptosis (Fulda et al., 2000; Longley et al., 2006).”
BackgroundMolecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Chemosensitization of tumors by resveratrol
Gupta, S. C., Kannappan, R., Reuter, S., Kim, J. H., & Aggarwal, B. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05852.x · Cited by 305
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00120 · Cited by 296
Targeting apoptosis for anticancer therapy
Fulda, S. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.002 · Cited by 231
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
Longley, D. B., Allen, W. L., & Johnston, P. G. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.001 · Cited by 171
Self-citationBagnoli, M., Canevari, S., & Mezzanzanica, D. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.015 · Cited by 170
Lewis, W., Day, B. J., Kohler, J. J., Hosseini, S. H., Chan, S. S. L., Green, E. C., Haase, C. P., Keebaugh, E. S., Long, R., Ludaway, T., et al. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700523 · Cited by 121
“It is associated with CPEO and Parkinsonism (20) and recently described to cause premature ovarian failure (21).”
BackgroundTurkington, R. C., Longley, D. B., Allen, W. L., Stevenson, L., McLaughlin, K., Dunne, P. D., Blayney, J. K., Salto-Tellez, M., Van Schaeybroeck, S., & Johnston, P. G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.10 · Cited by 98
“The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma Chemicals) assay was used to assess cell viability as previously described.(30)”
MethodSelf-citationWen, C., Chen, J., Zhang, D., Wang, H., Che, J., Qin, Q., He, L., Cai, Z., Lin, M., Lou, Q., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.007 · Cited by 35
Therapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
Self-citationThe histone deacetylase inhibitor entinostat/syndax 275 in osteosarcoma
Kiany, S., Harrison, D., & Gordon, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_7 · Cited by 24
Ranjan, K., Surolia, A., & Pathak, C. (2012) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-012-0166-2 · Cited by 23
Metadata
- Authors
- Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., & Johnston, P. G.
- Venue
- Oncogene
- Published
- 2005-10-17
- Volume
- 25
- Issue
- 6
- Pages
- 838-848
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2064862565
- Cited by
- 202
- References
- 8
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.